GlaxoSmithKline Pharmaceuticals · NSE: GLAXO · BSE: 500660
Q3 FY24 results · Oct–Dec 2023
GlaxoSmithKline Pharmaceuticals reported revenue from operations of ₹805.26 crore (up 0.4% from Q3 FY23) and net profit of ₹45.72 crore (down 72.2% from Q3 FY23) for Q3 FY24 (Oct–Dec 2023), on a consolidated basis.
| Item | Q3 FY24 | Q3 FY23 | YoY | Q2 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 805.26 | 802.30 | +0.4% | 956.99 | −15.9% |
| Other income | 28.11 | 23.42 | +20.0% | 28.21 | −0.4% |
| Total income | 833.37 | 825.72 | +0.9% | 985.20 | −15.4% |
| Profit before tax | 65.43 | 224.25 | −70.8% | 299.16 | −78.1% |
| Net profit for the period | 45.72 | 164.56 | −72.2% | 217.51 | −79.0% |
| EPS, basic (₹) | 9.89 | 9.71 | +1.9% | 12.84 | −23.0% |
| Net margin (%) | 5.7 | 20.5 | 22.7 |
| Item | Q3 FY24 | Q3 FY23 | YoY | Q2 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 804.98 | 799.11 | +0.7% | 953.38 | −15.6% |
| Other income | 28.34 | 23.60 | +20.1% | 28.47 | −0.5% |
| Total income | 833.32 | 822.71 | +1.3% | 981.85 | −15.1% |
| Profit before tax | 65.11 | 223.53 | −70.9% | 296.51 | −78.0% |
| Net profit for the period | 45.49 | 164.03 | −72.3% | 215.54 | −78.9% |
| EPS, basic (₹) | 9.88 | 9.68 | +2.1% | 12.72 | −22.3% |
| Net margin (%) | 5.7 | 20.5 | 22.6 |
Consolidated
- Filed with BSE
- 13 Feb 2024, 11:47 IST
- Board meeting
- 12 Feb 2024
- Period
- 01 Oct 2023 to 31 Dec 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 13 Feb 2024, 11:47 IST
- Board meeting
- 12 Feb 2024
- Period
- 01 Oct 2023 to 31 Dec 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE